Gemcitabine: Preclinical pharmacology and mechanisms of action

Seminars in Oncology

Volumn 23, Issue 5 SUPPL. 10, 1996, Pages 3-15

  Plunkett, W ^a   Huang, P ^a   Searcy, C E ^a   Gandhi, V ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; DEOXYCYTIDINE TRIPHOSPHATE; DEOXYRIBONUCLEOTIDE; DNA; DNA POLYMERASE; GEMCITABINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; NUCLEOTIDE; PYROPHOSPHATE; RIBONUCLEOTIDE REDUCTASE; RNA; TETRAHYDROURIDINE; THYMIDYLATE SYNTHASE;

CELL METABOLISM; CLINICAL TRIAL; DNA REPAIR; DNA SYNTHESIS; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; HUMAN; LEUKEMIA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DCMP DEAMINASE; DEOXYCYTIDINE; DNA; HUMANS; RIBONUCLEOTIDE REDUCTASES;

EID: 0029809541     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)